Results 31 to 40 of about 51,890 (248)

greenelab/multiple-myeloma-classifier: Reproducible Analysis for Multiple Myeloma Classifier

, 2019
Reproducible Analysis for Multiple Myeloma Classifier <p>The release stores all instructions to reproduce the analysis for the training and evaluating of a multi-class classifier to detect <em>KRAS</em>, <em>NRAS</em>, and ...
Greg Way
core   +1 more source

Cardiovascular toxicity of proteasome inhibitors in multiple myeloma therapy

, 2022
The treatment for multiple myeloma has advanced significantly over the past few decades. Proteasome inhibitors have become the cornerstone of the treatment of multiple myeloma.
Huang, Shan, Tse, Gary, Xie, Bingxin, Liu, Tong, Zhang, Nan, Zheng, Yi, Liu, Zhiqiang   +6 more
core   +1 more source

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma [PDF]

, 2023
To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of ...
Raje, Noopur, Munshi, Nikhil, Angela Dispenzieri, Moreau, Philippe, Anderson, Kenneth C., Noopur Raje, Mateos, Maria Victoria, Peter Voorhees, Maria-Victoria Mateos, Dispenzieri, Angela, Aurore Perrot, Brian G. Durie, Thierry Facon, Peter O’Gorman, Kumar, Shaji K., O’Donnell, Elizabeth K., Philippe Moreau, O’Gorman, Peter, Bladé, Joan, Kenneth C. Anderson, Nikhil Munshi, Lonial, Sagar, Voorhees, Peter, Perrot, Aurore, Richardson, Paul G., Laubach, Jacob P., Paul G. Richardson, Rosiñol, Laura, Durie, B., Elizabeth O’Donnell, Sagar Lonial, Facon, Thierry, Shaji Kumar, Joan Bladé, Laura Rosiñol, Jacob P. Laubach   +35 more
core   +1 more source

Multiple Myeloma [PDF]

Hematology, 2002
AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson, John D, Shaughnessy, Bart, Barlogie, Jean-Luc, Harousseau, G David, Roodman   +4 more
openaire   +2 more sources

Talquetamab in multiple myeloma

Haematologica, 2023
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting.
Lawrence Liu, Amrita Krishnan
doaj   +1 more source

Multiple Myeloma : an update on disease biology and therapy [PDF]

, 2004
Multiple myeloma is a malignancy of immunoglobulin producing plasma cells. Clinical features include bone pain due to lytic bone lesions or pathological fractures, anemia, symptomatic hypercalcemia, renal insufficiency, recurrent infections and ...
Dingli, David, Cook, Rachel J.
core  

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma

Blood Cancer Journal
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood.
Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S. Han, Rajib Shome, Kiyosumi Ochi, Cristina Panaroni, Keertik Fulzele, Farah Rexha, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, David T. Scadden, Noopur S. Raje   +14 more
doaj   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Multiple myeloma

Annals of Oncology, 2010
Multiple myeloma (MM) is the second most common hematological malignancy, with an incidence of 6/100,000 in Europe. Interactions between myeloma cells and the microenvironment are essential for MM cell survival. Better knowledge of disease biology has led to the introduction of novel agents for the management of myeloma patients.
Dimopoulos, M. A., Terpos, E.
openaire   +5 more sources